Dry Eye Syndrome

Ophthalmology
7
Pipeline Programs
6
Companies
18
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
7 programs
1
FID 112903Phase 41 trial
Nelfilcon A contact lensesN/A1 trial
SYSTANE® BALANCE Lubricant Eye DropsN/A1 trial
SYSTANE® Balance Lubricant Eye DropsN/A1 trial
SYSTANE® Gel Drop lubricant eye gelN/A1 trial
+2 more programs
Active Trials
NCT01614600Completed88Est. Sep 2012
NCT01733732CompletedEst. Oct 2013
NCT01223040Completed
+4 more trials
Thea Pharma
Thea PharmaMA - Waltham
4 programs
1
T2762Phase 31 trial
T2762N/A1 trial
T2769N/A1 trial
T2769N/A1 trial
Active Trials
NCT02617095TerminatedEst. Oct 2016
NCT03830359CompletedEst. Feb 2019
NCT06375499CompletedEst. Jan 2025
+1 more trials
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
1
1
Bromfenac Ophthalmic Solution APhase 31 trial
0.3% BOL-303242-X ophthalmic suspensionPhase 21 trial
Active Trials
NCT01163643Completed356Est. Jul 2011
NCT01212471Completed840Est. Dec 2011
BRIM Biotechnology
BRIM BiotechnologyTaiwan - Taipei
2 programs
1
1
BRM421Phase 2/31 trial
BRM421Phase 21 trial
Active Trials
NCT03066219CompletedEst. Jun 2017
NCT04343287CompletedEst. Jun 2020
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-319Phase 12 trials
Active Trials
NCT06977724Recruiting36Est. Mar 2029
NCT05512390Recruiting154Est. Feb 2027
Lumenis
LumenisAustralia - Chatswood
1 program
IPLN/A1 trial
Active Trials
NCT03396913Completed88Est. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AlconFID 112903
Thea PharmaT2762
Bausch + LombBromfenac Ophthalmic Solution A
BRIM BiotechnologyBRM421
BRIM BiotechnologyBRM421
Bausch + Lomb0.3% BOL-303242-X ophthalmic suspension
AbbVieABBV-319
AbbVieABBV-319
Thea PharmaT2769
Thea PharmaT2769
LumenisIPL
AlconSYSTANE® ULTRA Lubricant Eye Drops
Thea PharmaT2762
AlconSYSTANE® BALANCE Lubricant Eye Drops
AlconSYSTANE® Lid Wipes

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 1,747 patients across 18 trials

NCT01198782AlconFID 112903

Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%

Start: Sep 2010Est. completion: May 2011
Phase 4Completed
NCT02023268Thea PharmaT2762

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Start: Dec 2013Est. completion: Feb 2015
Phase 3Completed
NCT01212471Bausch + LombBromfenac Ophthalmic Solution A

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Start: Sep 2010Est. completion: Dec 2011840 patients
Phase 3Completed
NCT04343287BRIM BiotechnologyBRM421

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Start: Jan 2020Est. completion: Jun 2020
Phase 2/3Completed
NCT03066219BRIM BiotechnologyBRM421

Safety and Efficacy of BRM421 for Dry Eye Syndrome

Start: Feb 2017Est. completion: Jun 2017
Phase 2Completed
NCT01163643Bausch + Lomb0.3% BOL-303242-X ophthalmic suspension

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Start: Jul 2010Est. completion: Jul 2011356 patients
Phase 2Completed
NCT06977724AbbVieABBV-319

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

Start: Aug 2025Est. completion: Mar 202936 patients
Phase 1Recruiting
NCT05512390AbbVieABBV-319

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Start: Apr 2023Est. completion: Feb 2027154 patients
Phase 1Recruiting
NCT06375499Thea PharmaT2769

Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Start: Sep 2024Est. completion: Jan 2025
N/ACompleted
NCT03830359Thea PharmaT2769

Efficacy, Safety of T2769 in Dry Eye Disease

Start: Sep 2018Est. completion: Feb 2019
N/ACompleted
NCT03396913LumenisIPL

Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome

Start: Jan 2018Est. completion: Aug 201988 patients
N/ACompleted
NCT02446015AlconSYSTANE® ULTRA Lubricant Eye Drops

Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye

Start: Jun 2015Est. completion: Jun 2016159 patients
N/ACompleted
NCT02617095Thea PharmaT2762

Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

Start: Feb 2015Est. completion: Oct 2016
N/ATerminated
NCT01733732AlconSYSTANE® BALANCE Lubricant Eye Drops

SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers

Start: Mar 2013Est. completion: Oct 2013
N/ACompleted
NCT01733745AlconSYSTANE® Lid Wipes

SYSTANE® Family - Meibomian Deficiency

Start: Feb 2013Est. completion: Jun 201326 patients
N/ACompleted
NCT01614600AlconNelfilcon A contact lenses

Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers

Start: Jun 2012Est. completion: Sep 201288 patients
N/ACompleted
NCT01483989AlconSYSTANE® Gel Drop lubricant eye gel

In Vivo Measurement of Corneal Epithelial Changes in Dry Eye Patients

Start: Feb 2011Est. completion: Jun 2011
N/ACompleted
NCT01223040AlconSYSTANE® Balance Lubricant Eye Drops

An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry Eye

Start: Aug 2010
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,747 patients
6 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)